Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Towards Defining Primary and Secondary Non-Response in Rheumatoid Arthritis Patients Treated with Anti-TNFs: Results from the BioTRAC and OBRI Registries.

Keystone E, Rampakakis E, Movahedi M, Cesta A, Stutz M, Sampalis JS, Nantel F, Maslova K, Bombardier C.

J Rheumatol. 2019 Jul 1. pii: jrheum.190102. doi: 10.3899/jrheum.190102. [Epub ahead of print]

PMID:
31263067
2.

Collection of antirheumatic medication data from both patients and rheumatologists shows strong agreement in a real-world clinical cohort: the Ontario Best Practices Research Initiative-a rheumatoid arthritis cohort.

Movahedi M, Cesta A, Li X, Bombardier C; OBRI Investigators.

J Clin Epidemiol. 2019 Jun 18;114:95-103. doi: 10.1016/j.jclinepi.2019.06.012. [Epub ahead of print]

PMID:
31226411
3.

Frailty and risk of osteoporotic fractures in patients with rheumatoid arthritis: Data from the Ontario Best Practices Research Initiative.

Li G, Chen M, Li X, Cesta A, Lau A, Thabane L, Adachi JD, Tian J, Bombardier C.

Bone. 2019 Jun 8;127:129-134. doi: 10.1016/j.bone.2019.06.006. [Epub ahead of print]

PMID:
31185289
4.

Impact of residential area on the management of rheumatoid arthritis patients initiating their first biologic DMARD: Results from the Ontario Best Practices Research Initiative (OBRI).

Movahedi M, Joshi R, Rampakakis E, Thorne C, Cesta A, Sampalis JS, Bombardier C; Other OBRI Investigators.

Medicine (Baltimore). 2019 May;98(20):e15517. doi: 10.1097/MD.0000000000015517.

5.

Validation of Extensive Next-Generation Sequencing Method for Monogenic Disorder Analysis on Cell-Free Fetal DNA: Noninvasive Prenatal Diagnosis.

Dello Russo C, Cesta A, Longo S, Barone MA, Cima A, Mesoraca A, Sparacino D, Viola A, Giorlandino C.

J Mol Diagn. 2019 Jul;21(4):572-579. doi: 10.1016/j.jmoldx.2019.02.010. Epub 2019 Apr 25.

PMID:
31028936
6.

Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results.

Lau AN, Thorne JC, Movahedi M, Rampakakis E, Cesta A, Li X, Couto S, Sampalis J, Bombardier C; OBRI Investigators.

J Rheumatol. 2019 Aug;46(8):874-886. doi: 10.3899/jrheum.180486. Epub 2019 Apr 15.

PMID:
30988121
7.

A new role for Drosophila Aurora-A in maintaining chromosome integrity.

Merigliano C, Mascolo E, Cesta A, Saggio I, Vernì F.

Chromosoma. 2019 Mar;128(1):41-52. doi: 10.1007/s00412-018-00687-0. Epub 2019 Jan 5.

PMID:
30612150
8.

ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI).

Pope JE, Movahedi M, Rampakakis E, Cesta A, Sampalis JS, Keystone E, Thorne C, Bombardier C.

RMD Open. 2018 Nov 5;4(2):e000738. doi: 10.1136/rmdopen-2018-000738. eCollection 2018.

9.

Treatment patterns in rheumatoid arthritis after discontinuation of methotrexate: data from the Ontario Best Practices Research Initiative (OBRI).

Pope JE, Rampakakis E, Movahedi M, Cesta A, Li X, Couto S, Sampalis JS, Bombardier C; and the Ontario Best Practices Research Initiative investigators.

Clin Exp Rheumatol. 2018 Mar-Apr;36(2):215-222. Epub 2017 Oct 23.

10.

Predictors of patient decision to discontinue anti-rheumatic medication in patients with rheumatoid arthritis: results from the Ontario best practices research initiative.

Ahluwalia V, Rampakakis E, Movahedi M, Cesta A, Li X, Sampalis JS, Bombardier C.

Clin Rheumatol. 2017 Nov;36(11):2421-2430. doi: 10.1007/s10067-017-3805-4. Epub 2017 Sep 6.

PMID:
28879413
11.

ROBIN, a Telepresence Robot to Support Older Users Monitoring and Social Inclusion: Development and Evaluation.

Cortellessa G, Fracasso F, Sorrentino A, Orlandini A, Bernardi G, Coraci L, De Benedictis R, Cesta A.

Telemed J E Health. 2018 Feb;24(2):145-154. doi: 10.1089/tmj.2016.0258. Epub 2017 Aug 3.

PMID:
28771398
12.

Anthracycline-based induction chemotherapy followed by concurrent cyclophosphamide, methotrexate and 5-fluorouracil and radiation therapy in surgically resected axillary node-positive breast cancer.

Recchia F, Candeloro G, Cesta A, DI Staso M, Bonfili P, Gravina GL, DI Cesare E, Necozione S, Rea S.

Mol Clin Oncol. 2014 May;2(3):473-478. Epub 2014 Mar 21.

13.

Vascular endothelial growth factor expression and T-regulatory cells in premenopausal breast cancer.

Recchia F, Candeloro G, Necozione S, Desideri G, Cesta A, Recchia L, Rea S.

Oncol Lett. 2013 Apr;5(4):1117-1122. Epub 2013 Jan 18.

14.

Research on cognitive robotics at the Institute of Cognitive Sciences and Technologies, National Research Council of Italy.

Pezzulo G, Baldassarre G, Cesta A, Nolfi S.

Cogn Process. 2011 Nov;12(4):367-74. doi: 10.1007/s10339-011-0402-3. Epub 2011 Apr 6. No abstract available.

PMID:
21468745
15.

Paralytic ileus associated with capecitabine.

Laudadio L, Biondi E, D'Ostilio N, Cesta A, Di Giandomenico F, Forciniti S, Nuzzo A.

Tumori. 2008 Sep-Oct;94(5):742-5.

PMID:
19112951
16.

Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3.

Tang CI, Loblaw DA, Cheung P, Holden L, Morton G, Basran PS, Tirona R, Cardoso M, Pang G, Gardner S, Cesta A.

Clin Oncol (R Coll Radiol). 2008 Dec;20(10):729-37. doi: 10.1016/j.clon.2008.08.006. Epub 2008 Oct 5.

PMID:
18838256
17.

Medication reconciliation at hospital discharge: evaluating discrepancies.

Wong JD, Bajcar JM, Wong GG, Alibhai SM, Huh JH, Cesta A, Pond GR, Fernandes OA.

Ann Pharmacother. 2008 Oct;42(10):1373-9. doi: 10.1345/aph.1L190.

PMID:
18780806
18.

A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer.

Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G, Carta G, Necozione S, Mantovani G, Rea S.

Gynecol Oncol. 2007 Jul;106(1):164-9. Epub 2007 May 3.

PMID:
17481704
19.

Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinoma.

Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G, Necozione S, Fumagalli L, Rea S.

J Immunother. 2007 May-Jun;30(4):448-54.

PMID:
17457219
20.

Chemoimmunotherapy in the treatment of metastatic gastric cancer.

Recchia F, Saggio G, Candeloro G, Cesta A, Amiconi G, Blasio AD, Necozione S, Rea S.

Anticancer Drugs. 2007 Jun;18(5):597-604.

PMID:
17414629
21.

Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer.

Recchia F, Saggio G, Cesta A, Candeloro G, Di Blasio A, Amiconi G, Lombardo M, Nuzzo A, Lalli A, Alesse E, Necozione S, Rea S.

Cancer Immunol Immunother. 2007 May;56(5):699-708. Epub 2006 Sep 6.

PMID:
16955297
22.

Dose-finding study of docetaxel added to ifosfamide and cisplatin followed by concomitant capecitabine and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.

Recchia F, Saggio G, Cesta A, Amiconi G, di Blasio A, Candeloro G, Valeriani M, Tombolini V, Rea S.

Anticancer Res. 2006 May-Jun;26(3B):2317-24.

23.
24.

The EMITT study: development and evaluation of a medication information transfer tool.

Cesta A, Bajcar JM, Ong SW, Fernandes OA.

Ann Pharmacother. 2006 Jun;40(6):1074-81. Epub 2006 May 30.

PMID:
16735652
25.

Cardiac metastases in malignant fibrous histiocytoma. A case report.

Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G, Rea S, Nappi G.

Tumori. 2006 Jan-Feb;92(1):76-8.

PMID:
16683388
26.

Drug-related problems on hospital admission: relationship to medication information transfer.

Ong SW, Fernandes OA, Cesta A, Bajcar JM.

Ann Pharmacother. 2006 Mar;40(3):408-13. Epub 2006 Feb 21.

PMID:
16492794
27.
28.

Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer.

Recchia F, Saggio G, Nuzzo A, Biondi E, Di Blasio A, Cesta A, Candeloro G, Alesse E, Rea S.

J Immunother. 2006 Jan-Feb;29(1):87-94.

PMID:
16365604
29.

Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer.

Recchia F, Saggio G, Cesta A, Candeloro G, Nuzzo A, Lombardo M, Carta G, Rea S.

Int J Oncol. 2005 Oct;27(4):1039-46.

PMID:
16142321
30.
31.

High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer.

Mattioli R, Massacesi C, Recchia F, Marcucci F, Cappelletti C, Imperatori L, Pilone A, Rocchi M, Cesta A, Laici G, Bonsignori M, Lippe P.

Ann Oncol. 2005 Jul;16(7):1147-51. Epub 2005 Apr 22.

PMID:
15849224
32.

Paclitaxel plus gemcitabine in advanced non-small cell lung cancer patients with low performance status.

Recchia F, Saggio G, Cesta A, Candeloro G, Rea S.

Anticancer Res. 2005 Jan-Feb;25(1B):409-14.

33.
34.

Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists.

Verma S, Kerr-Cresswell D, Dranitsaris G, Charbonneau F, Trudeau M, Yogendran G, Cesta AM, Clemons M.

Support Care Cancer. 2004 Dec;12(12):852-8. Epub 2004 Aug 21.

PMID:
15322969
35.

Do physicians follow systemic treatment and funding policy guidelines?

Clemons M, Enright K, Cesta A, Charbonneau F, Chow E, Warr D, Kee-Cresswell D, Chang J, Yogendran G, Trudeau M, De Angelis C, Cottrell W, Dranitsaris G.

Can J Clin Pharmacol. 2004 Spring;11(1):e168-78.

PMID:
15300959
36.

Sleep assessment in a population-based study of chronic fatigue syndrome.

Unger ER, Nisenbaum R, Moldofsky H, Cesta A, Sammut C, Reyes M, Reeves WC.

BMC Neurol. 2004 Apr 19;4:6.

37.

Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer.

Recchia F, De Filippis S, Saggio G, Amiconi G, Cesta A, Carta G, Rea S.

Anticancer Drugs. 2003 Sep;14(8):633-8.

PMID:
14501385
38.

Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer.

Recchia F, De Filippis S, Rosselli M, Saggio G, Cesta A, Fumagalli L, Rea S.

Clin Cancer Res. 2001 May;7(5):1251-7.

39.

Toward interactive scheduling systems for managing medical resources.

Oddi A, Cesta A.

Artif Intell Med. 2000 Oct;20(2):113-38.

PMID:
10936749
40.

Determination of diamine oxidase in lentil seedlings by enzymic activity and immunoreactivity.

Federico R, Angelini R, Cesta A, Pini C.

Plant Physiol. 1985 Sep;79(1):62-4.

Supplemental Content

Support Center